Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. Read why I rate the ADPT stock a Buy for long-term investors.
T Cells: The Forgotten Warrior in the COVID-19 Battle biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Science Writer
Adaptive Biotechnologies recently received FDA Emergency Use Authorization (EUA) for T-Detect⢠COVID, a test that detects the unique T-cell signature specific to SARS-CoV-2. T-Detect COVID is the first clinical test launched from Adaptiveâs TCR-Antigen Map collaboration with Microsoft, highlighting the potential of using T cells in the blood to detect multiple diseases.
To learn more about T-Detect, its development and how it compares to antibody testing,
Technology Networks spoke to Dr Sudeb Dalai, senior medical director at Adaptive Biotechnologies. In this interview, Sudeb also discusses the role that T-cell analysis may play in the diagnosis and treatment of diseases in the future.
How The Global Pandemic Is Fueling Increased Revenue Opportunities For Healthcare Stocks
- Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., March 17, 2021 /PRNewswire/ While many industries have suffered during the global pandemic, there are those few whose fortunes are being made because of COVID. The Personal Protective Equipment Market is one of the latter industries. The mass spread infection scale of COVID-19 has led to a burgeoning demand for PPEs around the globe, which is estimated to be elevated during the course of the current pandemic. The COVID-19 pandemic has had such positive impact on the market due to increasing demand for a wide range of PPE, such as gloves, masks, face-shields, and coveralls, especially from the healthcare sector, to avoid the spread of the virus. These special equipment items create a barrier between the personnel and germs often found in the medical environments. The barrier blocks the transmiss
This T cell-based test is the first indication resulting from Adaptive s TCR-Antigen Map collaboration with
Microsoft Corporation (NASDAQ: MSFT).
Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection.
The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%.
The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.